Gilead Advancing Access for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)

Gilead Advancing Access helps people find coverage and financial options for Gilead medicines. The Biktarvy co-pay program gives commercially insured patients up to $7,200 per calendar year, and uninsured patients may receive medicine at no charge for up to 12 months.

Help offered: copay savings card, free drug for uninsured (PAP), insurance navigation / benefits verification.

Co-pay savings card is not valid for prescriptions reimbursable by Medicare, Medicare Part D, Medicaid, TRICARE, VA or DOD. The Medication Assistance Program is for uninsured people.

Eligibility changes often. Confirm details on the official program page linked below before applying.